Published in Leukemia on November 16, 2006
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood (2008) 2.04
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther (2010) 1.45
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol (2008) 1.42
Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold. Org Lett (2009) 1.23
Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? Arthritis Res Ther (2008) 1.15
Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS One (2011) 1.09
Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg Med Chem Lett (2007) 0.98
Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors. J Med Chem (2008) 0.93
Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol (2008) 0.92
Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res (2008) 0.92
Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One (2012) 0.91
Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol (2012) 0.90
Potential implication of the chemical properties and bioactivity of nitrone spin traps for therapeutics. Future Med Chem (2012) 0.86
The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorg Med Chem Lett (2011) 0.85
Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxid Redox Signal (2014) 0.82
Superoxide radical anion adduct of 5,5-dimethyl-1-pyrroline N-oxide. 6. Redox properties. J Phys Chem A (2010) 0.82
Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry. ACS Med Chem Lett (2012) 0.81
HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process. Cancer Biol Ther (2014) 0.80
Histone deacetylases in kidney development: implications for disease and therapy. Pediatr Nephrol (2012) 0.79
First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2013) 0.78
Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors. ACS Med Chem Lett (2014) 0.75
Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties. Invest New Drugs (2015) 0.75
gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia (2010) 3.46
Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene (2006) 1.22
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res (1997) 1.16
Chromatin modifications and DNA double-strand breaks: the current state of play. Leukemia (2006) 1.01
Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene (2007) 1.00
Double-strand breaks: signaling pathways and repair mechanisms. Cell Mol Life Sci (2004) 0.97
Epigenetic changes in diabetes. Clin Genet (2013) 0.90
Immunomodulatory effects of histone deacetylase inhibitors. Curr Mol Med (2013) 0.87
Epigenetic and genetic mechanisms of abnormal 11p15 genomic imprinting in Silver-Russell and Beckwith-Wiedemann syndromes. Curr Med Chem (2011) 0.80
Functional links between transcription, DNA repair and apoptosis. Cell Mol Life Sci (2004) 0.79